Commonwealth Equity Services, LLC Amicus Therapeutics, Inc. Transaction History

Commonwealth Equity Services, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 04, 2021	SELL	$9.2 - $23.86 $80,196 - $207,987	-8,717 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$13.47 - $24.89 $117,417 - $216,966	8,717 New	8,717 $201,000
Q4 2019 Feb 05, 2020	SELL	$7.48 - $10.75 $229,344 - $329,605	-30,661 Closed	0 $0
Q3 2019 Oct 30, 2019	BUY	$8.02 - $13.25 $802 - $1,325	100 Added 0.33%	30,661 $245,000
Q2 2019 Jul 19, 2019	SELL	$10.96 - $14.4 $2,192 - $2,880	-200 Reduced 0.65%	30,561 $381,000
Q1 2019 May 13, 2019	SELL	$10.04 - $13.92 $1,104 - $1,531	-110 Reduced 0.36%	30,761 $418,000
Q4 2018 Feb 11, 2019	SELL	$8.38 - $13.44 $7,458 - $11,961	-890 Reduced 2.8%	30,871 $295,000
Q3 2018 Nov 06, 2018	BUY	$11.6 - $16.54 $2,320 - $3,308	200 Added 0.63%	31,761 $383,000
Q2 2018 Jul 31, 2018	SELL	$13.13 - $17.09 $328 - $427	-25 Reduced 0.08%	31,561 $493,000
Q1 2018 May 14, 2018	BUY	$13.76 - $17.12 $14,792 - $18,404	1,075 Added 3.52%	31,586 $475,000
Q4 2017 Feb 12, 2018	BUY	$12.51 - $16.24 $381,692 - $495,498	30,511	30,511 $439,000

311

312M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.7B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.